{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:53:46Z","timestamp":1793832826034,"version":"4.6.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.urolonc.2021.07.007","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T09:18:31Z","timestamp":1634116711000},"page":"11.e9-11.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: Results of a prospective European Multicentre study at 15 months from treatment start"],"prefix":"10.1016","volume":"40","author":[{"given":"Rodolfo","family":"Hurle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Guazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiuseppe","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavio","family":"De Cobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettore Di","family":"Trapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Nohales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llorente","family":"Carlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Duran-Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Lazzeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2021.07.007_bib0001","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.07.007_bib0002","doi-asserted-by":"crossref","first-page":"259","DOI":"10.5489\/cuaj.1997","article-title":"Postoperative mortality and complications after radical cystectomy for bladder cancer in Quebec: A population-based analysis during the years 2000-2009","volume":"8","author":"Zakaria","year":"2014","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.urolonc.2021.07.007_bib0003","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ucl.2017.12.008","article-title":"Quality of Life After Radical Cystectomy","volume":"45","author":"Tyson","year":"2018","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urolonc.2021.07.007_bib0004","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drug","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.urolonc.2021.07.007_bib0005","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","article-title":"Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation","volume":"37","author":"Gelderblom","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2021.07.007_bib0006","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","article-title":"Hypersensitivity reactions from taxol","volume":"8","author":"Weiss","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.07.007_bib0007","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s002800050973","article-title":"Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment","volume":"44","author":"Knemeyer","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.urolonc.2021.07.007_bib0008","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.urolonc.2005.08.020","article-title":"HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer","volume":"24","author":"Rosato","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2021.07.007_bib0009","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.juro.2010.09.073","article-title":"Paclitaxel-hyaluronic Acid for Intravesical Therapy of Bacillus Calmette-Gu\u00e9rin Refractory Carcinoma in Situ of the Bladder: Results of a Phase I","volume":"185","author":"Bassi","year":"2011","journal-title":"Study J Urol"},{"key":"10.1016\/j.urolonc.2021.07.007_bib0010","doi-asserted-by":"crossref","first-page":"e1056","DOI":"10.1016\/S1569-9056(18)31567-7","article-title":"Oncofid-P-B (paclitaxel-hyaluronic acid) in the intravesical therapy of patients affected by primary or recurrent Ta G1-G2 papillary cancer of the bladder. A phase II marker lesion study","volume":"17","author":"Bassi","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.07.007_bib0011","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.euo.2020.02.006","article-title":"Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis","volume":"3","author":"Kamat","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2021.07.007_bib0012","unstructured":"Common Terminology Criteria for Adverse Events. Version 4.03 (June 14, 2010 ), NIH-NCI"},{"key":"10.1016\/j.urolonc.2021.07.007_bib0013","unstructured":"EAU Guidelines on Non-muscle invasive Bladder Cancer; at https:\/\/uroweb.org\/guideline\/non-muscle-invasive-bladder-cancer\/"},{"key":"10.1016\/j.urolonc.2021.07.007_bib0014","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","article-title":"Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Gu\u00e9rin","volume":"31","author":"Dinney","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2021.07.007_bib0015","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2021.07.007_bib0016","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/JU.0000000000000297","article-title":"Emerging Immunotherapy Options for Bacillus Calmette-Gu\u00e9rin Unresponsive Nonmuscle Invasive Bladder Cancer","volume":"202","author":"Meng","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.07.007_bib0017","article-title":"FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer","author":"Wright","year":"2020","journal-title":"Case Medical Research"},{"key":"10.1016\/j.urolonc.2021.07.007_bib0018","article-title":"Intravesical nadofaragene firadenoved gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single arm, open label, repeat-dose clinical trial","author":"Boorjian","year":"2020","journal-title":"Lancet Oncology"},{"key":"10.1016\/j.urolonc.2021.07.007_bib0019","article-title":"Phase 3 study of Vicinium in BCG-unresponsive non-muscle invasive bladder cancer: initial results","author":"Dickstein","year":"2019","journal-title":"AUA"},{"key":"10.1016\/j.urolonc.2021.07.007_bib0020","article-title":"Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non\u2013muscle-invasive bladder cancer after BCG failure","author":"Hurle","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2021.07.007_bib0021","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.juro.2012.10.068","article-title":"Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guerin therapy","volume":"189","author":"Barlow","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.07.007_bib0022","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1016\/j.juro.2016.03.084","article-title":"A phase 1\/2 study of albumin bound rapamycin nanoparticles in bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer","volume":"195","author":"McKiernan","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.07.007_bib0023","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000000919","article-title":"A Phase 1 Trial of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin for the Treatment of Non-Muscle Invasive BCG Unresponsive or Recurrent\/Relapsing Urothelial Carcinoma of the Bladder","author":"DeCastro","year":"2020","journal-title":"J. Urol."},{"key":"10.1016\/j.urolonc.2021.07.007_bib0024","doi-asserted-by":"crossref","first-page":"35 e15","DOI":"10.1016\/j.urolonc.2013.01.009","article-title":"Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer","volume":"32","author":"Lightfoot","year":"2014","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.07.007_bib0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2021.07.007_bib0026","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.euo.2020.02.006","article-title":"Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis","volume":"3","author":"Kamat","year":"2020","journal-title":"Eur Urol Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921003082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921003082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:22:32Z","timestamp":1761042152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143921003082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1078143921003082"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.07.007","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: Results of a prospective European Multicentre study at 15 months from treatment start","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}